These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

343 related items for PubMed ID: 21606568

  • 21. The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial.
    Raskind MA, Peskind ER, Truyen L, Kershaw P, Damaraju CV.
    Arch Neurol; 2004 Feb; 61(2):252-6. PubMed ID: 14967774
    [Abstract] [Full Text] [Related]

  • 22. Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study.
    Mohs RC, Shiovitz TM, Tariot PN, Porsteinsson AP, Baker KD, Feldman PD.
    Am J Geriatr Psychiatry; 2009 Sep; 17(9):752-9. PubMed ID: 19700948
    [Abstract] [Full Text] [Related]

  • 23. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion.
    Alvarez XA, Mouzo R, Pichel V, Pérez P, Laredo M, Fernández-Novoa L, Corzo L, Zas R, Alcaraz M, Secades JJ, Lozano R, Cacabelos R.
    Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):633-44. PubMed ID: 10669911
    [Abstract] [Full Text] [Related]

  • 24. Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease.
    Burns A, Gauthier S, Perdomo C.
    Int J Geriatr Psychiatry; 2007 Aug; 22(8):806-12. PubMed ID: 17199235
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial.
    Burns A, Bernabei R, Bullock R, Cruz Jentoft AJ, Frölich L, Hock C, Raivio M, Triau E, Vandewoude M, Wimo A, Came E, Van Baelen B, Hammond GL, van Oene JC, Schwalen S.
    Lancet Neurol; 2009 Jan; 8(1):39-47. PubMed ID: 19042161
    [Abstract] [Full Text] [Related]

  • 29. Post hoc comparison of daily rates of nausea and vomiting with once- and twice-daily galantamine from a double-blind, placebo-controlled, parallel-group, 6-month study.
    Dunbar F, Zhu Y, Brashear HR.
    Clin Ther; 2006 Mar; 28(3):365-72. PubMed ID: 16750451
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia.
    Erkinjuntti T, Kurz A, Small GW, Bullock R, Lilienfeld S, Damaraju CV, GAL-INT-6 Study Group.
    Clin Ther; 2003 Jun; 25(6):1765-82. PubMed ID: 12860497
    [Abstract] [Full Text] [Related]

  • 33. Galantamine treatment in outpatients with mild Alzheimer's disease.
    Richarz U, Gaudig M, Rettig K, Schauble B.
    Acta Neurol Scand; 2014 Jun; 129(6):382-92. PubMed ID: 24461047
    [Abstract] [Full Text] [Related]

  • 34. Long-term effects of galantamine on cognitive function in Alzheimer's disease: a large-scale international retrospective study.
    Kavanagh S, Van Baelen B, Schäuble B.
    J Alzheimers Dis; 2011 Jun; 27(3):521-30. PubMed ID: 21891871
    [Abstract] [Full Text] [Related]

  • 35. Galantamine provides sustained benefits in patients with 'advanced moderate' Alzheimer's disease for at least 12 months.
    Blesa R, Davidson M, Kurz A, Reichman W, van Baelen B, Schwalen S.
    Dement Geriatr Cogn Disord; 2003 Jun; 15(2):79-87. PubMed ID: 12566596
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial.
    Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV.
    Lancet; 2002 Apr 13; 359(9314):1283-90. PubMed ID: 11965273
    [Abstract] [Full Text] [Related]

  • 40. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.
    Raskind MA, Peskind ER, Wessel T, Yuan W.
    Neurology; 2000 Jun 27; 54(12):2261-8. PubMed ID: 10881250
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.